Search Result

Results for "

CD2 Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CD2 (2) Antibiotic (1) Autophagy (1) Bacterial (1) Cytochrome P450 (1) FKBP (1) GABA Receptor (2) HBV (1) iGluR (2) Isotope-Labeled Compounds (6) Opioid Receptor (1) Phosphatase (1) Potassium Channel (2) TGF-beta/Smad (2)
By Research Areas:	Cancer (6) Cardiovascular Disease (2) Endocrinology (1) Infection (2) Inflammation/Immunology (2) Metabolic Disease (2) Neurological Disease (5)

Inhibitors & Agonists

Inhibitory Antibodies

Isotope-Labeled Compounds

Targets Recommended: CD2 Serpin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99904

Siplizumab MEDI-507	CD2	Inflammation/Immunology Cancer
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against *CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites* T cell proliferation and enriches naïve and bona fide regulatory T cells .

HY-13756S

Tacrolimus-13C,d2 FK506-¹³C,d₂; Fujimycin-¹³C,d₂; FR900506-¹³C,d₂	Phosphatase FKBP Bacterial Autophagy Antibiotic	Infection Inflammation/Immunology Cancer
Tacrolimus- ¹³C,d₂ is a ¹³C-labeled and deuterium labeled Tacrolimus. Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .

HY-W654247

Lamivudine-13C,d2	HBV	Infection Cancer
Lamivudine- ¹³C,d₂ is the deuterium labeled and ¹³C-labeled Lamivudine. Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS .

HY-P990286

Anti-Rat CD2 Antibody (OX-34)	CD2	Others
Anti-Rat CD2 Antibody (OX-34) is a -derived type antibody inhibitor, targeting to rat CD2.

HY-A0118S1

Naloxegol-13C,d2 NKTR-118-¹³C_{,d₂; AZ-13337019-¹³C_,d₂}	Isotope-Labeled Compounds Opioid Receptor	Neurological Disease Cancer
Naloxegol- ¹³C,d₂ (NKTR-118- ¹³C,d₂) is ¹³C labeled Naloxegol. Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .

HY-B0033S

Vigabatrin-13C,d2 hydrochloride γ-Vinyl-GABA-¹³C,d₂ hydrochloride	Isotope-Labeled Compounds GABA Receptor	Neurological Disease
Vigabatrin- ¹³C,d₂ (hydrochloride) is the ¹³C- and deuterium labeled Vigabatrin (hydrochloride). Vigabatrin hydrochloride (γ-Vinyl-GABA hydrochloride), a inhibitory neurotransmitter GABA vinyl-derivative, is an orally active and irreversible GABA transaminase inhibitor. Vigabatrin hydrochloride is an antiepileptic agent, which acts by increasing GABA levels in the brain by inhibiting the catabolism of GABA by GABA transaminase .

HY-W778008

Rac-Vigabatrin-13C,d2 (Major)	Isotope-Labeled Compounds GABA Receptor	Neurological Disease
Rac-Vigabatrin- ¹³C,d₂ (Major) is the deuterium and ¹³C labeled Vigabatrin (HY-15399). Vigabatrin (γ-Vinyl-GABA), an inhibitory neurotransmitter GABA vinyl-derivative, is an orally active and irreversible GABA transaminase inhibitor. Vigabatrin is an antiepileptic agent, which acts by increasing GABA levels in the brain by inhibiting the catabolism of GABA by GABA transaminase .

HY-13632S5

Exemestane-13C,d2 FCE 24304-¹³C,d₂; EXE-¹³C,d₂	Cytochrome P450 Isotope-Labeled Compounds	Endocrinology Cancer
Exemestane- ¹³C,d₂ is ¹³C and deuterated labeled Exemestane (HY-13632). Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC₅₀s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .

HY-B0252S1

Hydrochlorothiazid-13C,d2 HCTZ-¹³C,d₂	Isotope-Labeled Compounds TGF-beta/Smad Potassium Channel	Cardiovascular Disease Metabolic Disease
Hydrochlorothiazid- ¹³C,d₂ is the ¹³C- and deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-B0252S3

Hydrochlorothiazide-15N2,13C,d2 HCTZ-¹⁵N₂,¹³C,d₂	Potassium Channel TGF-beta/Smad Isotope-Labeled Compounds	Cardiovascular Disease Metabolic Disease Cancer
Hydrochlorothiazide- ¹⁵N₂, ¹³C,d₂ is ¹⁵N and deuterated labeled Hydrochlorothiazide (HY-B0252). Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-15703

QNZ46 1 Publications Verification	iGluR	Neurological Disease
QNZ46 is a highly selective noncompetitive NMDA receptor antagonist targeting *GluN2C/D* (IC₅₀=3.9 μM), GluN1/GluN2C (IC₅₀=7.1 μM), and GluN1/GluN2D (IC₅₀=182 μM) subunits. QNZ46 inhibits glutamate-mediated calcium influx, thereby blocking excitotoxicity. QNZ46 is membrane permeable and can cross the blood-brain barrier, where it inhibits myelin damage and axonal degeneration .

HY-155811

DQP-997-74	iGluR	Neurological Disease
DQP-997-74 (compound 2i) is a selective negative allosteric modulator of N-methyl-d-aspartate receptor (NMDAR), specifically targeting *GluN2C/D* (IC₅₀: 0.069 μM and 0.035 μM), with blood-brain barrier penetrability. Where DQP refers to dihydroquinoline-pyrazoline. DQP-997-74 acts synergistically with the agonist glutamate to exhibit time-dependent enhanced potency in inhibiting hypersynchronous activity driven by high-frequency excitatory synaptic transmission. DQP-997-74 reduces the number of epileptogenesis in a murine model of tuberous sclerosis complex (TSC)-induced epilepsy. DQP-997-74 can be used for research on NMDAR-related neurological diseases .

Cat. No.	Product Name	Target	Research Area

HY-P99904

Siplizumab MEDI-507	CD2	Inflammation/Immunology Cancer
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against *CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites* T cell proliferation and enriches naïve and bona fide regulatory T cells .

HY-P990286

Anti-Rat CD2 Antibody (OX-34)	CD2	Others
Anti-Rat CD2 Antibody (OX-34) is a -derived type antibody inhibitor, targeting to rat CD2.

Cat. No.	Product Name	Chemical Structure

HY-13756S

Tacrolimus-13C,d2
Tacrolimus- ¹³C,d₂ is a ¹³C-labeled and deuterium labeled Tacrolimus. Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .

HY-W654247

Lamivudine-13C,d2
Lamivudine- ¹³C,d₂ is the deuterium labeled and ¹³C-labeled Lamivudine. Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS .

HY-A0118S1

Naloxegol-13C,d2
Naloxegol- ¹³C,d₂ (NKTR-118- ¹³C,d₂) is ¹³C labeled Naloxegol. Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .

HY-B0033S

Vigabatrin-13C,d2 hydrochloride
Vigabatrin- ¹³C,d₂ (hydrochloride) is the ¹³C- and deuterium labeled Vigabatrin (hydrochloride). Vigabatrin hydrochloride (γ-Vinyl-GABA hydrochloride), a inhibitory neurotransmitter GABA vinyl-derivative, is an orally active and irreversible GABA transaminase inhibitor. Vigabatrin hydrochloride is an antiepileptic agent, which acts by increasing GABA levels in the brain by inhibiting the catabolism of GABA by GABA transaminase .

Vigabatrin-13C,d2 hydrochloride

Vigabatrin- ¹³C,d₂ (hydrochloride) is the ¹³C- and deuterium labeled Vigabatrin (hydrochloride). Vigabatrin hydrochloride (γ-Vinyl-GABA hydrochloride), a inhibitory neurotransmitter GABA vinyl-derivative, is an orally active and irreversible GABA transaminase inhibitor. Vigabatrin hydrochloride is an antiepileptic agent, which acts by increasing GABA levels in the brain by inhibiting the catabolism of GABA by GABA transaminase .

HY-W778008

Rac-Vigabatrin-13C,d2 (Major)
Rac-Vigabatrin- ¹³C,d₂ (Major) is the deuterium and ¹³C labeled Vigabatrin (HY-15399). Vigabatrin (γ-Vinyl-GABA), an inhibitory neurotransmitter GABA vinyl-derivative, is an orally active and irreversible GABA transaminase inhibitor. Vigabatrin is an antiepileptic agent, which acts by increasing GABA levels in the brain by inhibiting the catabolism of GABA by GABA transaminase .

HY-13632S5

Exemestane-13C,d2
Exemestane- ¹³C,d₂ is ¹³C and deuterated labeled Exemestane (HY-13632). Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC₅₀s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .

HY-B0252S1

Hydrochlorothiazid-13C,d2
Hydrochlorothiazid- ¹³C,d₂ is the ¹³C- and deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

Hydrochlorothiazid-13C,d2

Hydrochlorothiazid- ¹³C,d₂ is the ¹³C- and deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-B0252S3

Hydrochlorothiazide-15N2,13C,d2
Hydrochlorothiazide- ¹⁵N₂, ¹³C,d₂ is ¹⁵N and deuterated labeled Hydrochlorothiazide (HY-B0252). Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

Hydrochlorothiazide-15N2,13C,d2

Hydrochlorothiazide- ¹⁵N₂, ¹³C,d₂ is ¹⁵N and deuterated labeled Hydrochlorothiazide (HY-B0252). Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.